<DOC>
	<DOCNO>NCT02136992</DOCNO>
	<brief_summary>Pirfenidone anti-fibrosis drug develop recent year demonstrate potential anti- fibrotic effect , far domestic study pirfenidone 's efficacy safety evaluation china . The aim study evaluate efficacy safety pirfenidone patient idiopathic pulmonary fibrosis ( IPF ) observation large sample clinical case .</brief_summary>
	<brief_title>Clinical Efficacy Safety Pirfenidone Patients With Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description>The aim study evaluate efficacy safety pirfenidone patient idiopathic pulmonary fibrosis ( IPF ) observation large sample clinical case . During observation , study visit occur end 12w , 24w , 36w , 48w.all participant require check various efficacy safety indicator .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>1 . Written inform consent sign ; 2 . Age ≤75 year ; 3 . Clinically multidisciplinary diagnose idiopathic pulmonary fibrosis ( see 2011 guidance ) ; 4 . Resting state PaO2≥50mg , FVC % ≥45 % normal predict value DLCO≥30 % normal predict value . 1 . Allergic pirfenidone ; 2 . Patients serious Significant pulmonary infection need antiinfection treatment ; 3 . Patients take interferon , penicillamine agent treatment IPF ; 4 . Patients take prednisone ( ≥50mg ) glucocorticoid past 1 month ; 5 . Patients take immunosuppressant past 1 month ; 6 . Patients take amiodarone may cause pulmonary fibrosis past 3 month ; 7 . Patients malignant tumor past 5 year ; 8 . Participated clinical trial past 3 month ; 9 . Patients serious heart disease ( NYHA class ⅢⅣ ) , liver disease ( ALT AST 2 time upper level normal value range ) , kidney disease ( Cr upper level normal value range ) ; 10 . Pregnant lactating woman ; 11 . The investigator assess inappropriate participate clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>